
    
      PRIMARY OBJECTIVES:

      I. To determine the response rates following treatment with PD 0332991 in the following
      malignancies: 1) Metastatic breast cancer, 2) Metastatic colorectal cancer, 3) Metastatic
      melanoma with CDK4 mutation or amplification, or 4) Cisplatin-refractory, unresectable germ
      cell tumors.

      OUTLINE:

      Patients receive oral PD 0332991 once daily on days 1-21. Treatment repeats every 28 days for
      up to 12 courses in the absence of unacceptable toxicity or disease progression.
    
  